Last updated: 2026-09-09 10:17:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Tyra Biosciences, Inc. (TYRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $26.92, with a market capitalisation of $1.71B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.70 to $40.65. This page covers its latest market performance, valuation, price trends and company information.
$1.71B | |
$26.50 | |
$40.65 | |
$4.93 | |
$26.73 | |
2.20K | |
751.53K | |
-- | |
$40.65 | |
$11.70 | |
-- | |
-- |
Tyra Biosciences, Inc. (TYRA) is trading at $26.92 in pre-market trading as of 2026-09-09 10:01:00, up 0.70% ($0.19) from the previous close of $26.73
Pre-market trading shows how investors are pricing TYRA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Tyra Biosciences, Inc. (TYRA) moved from $24.94 to $26.92, representing a gain of 7.93% ($1.98).
The stock traded between $24.17 and $29.56 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 751.38 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 52.6%
TYRA is currently trading at $26.92, placing it 52.6% of the way from its 52-week low of $11.70 to its 52-week high of $40.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tyra Biosciences, Inc. (TYRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.